Exosome / Extracellular Vesicle CDMOs — Ranked by Signal Score
Exosome and extracellular vesicle CDMOs provide manufacturing of next-generation delivery platforms for RNA therapeutics, proteins, and small molecules. This emerging modality requires specialized isolation, characterization, and scale-up capabilities.
7
CDMOs
6
Fully scored
| # | CDMO | Signal Score | Quality | Capacity | Programs |
|---|---|---|---|---|---|
| 1 |
EXO
ExoXpert (EXO Biologics)
Liege, BE
|
56.5 | — | — | 0 programs |
| 2 |
EA
Esco Aster
Singapore, SG
|
63.0 | — | — | 0 programs |
| 3 |
EV
Evox Therapeutics
Oxford, UK
|
57.5 | — | — | 0 programs |
| 4 |
CK
Codiak BioSciences (Sarepta)
Cambridge, MA
|
78.0 | 100.0 | — | 16 programs |
| 5 |
EP
Exopharm
Melbourne, AU
|
56.5 | — | — | 0 programs |
| 6 |
CLB
Clara Biotech
Indianapolis, IN
|
56.5 | — | — | 0 programs |
| — |
CoJourney Inc.
Ambler, PA (US operations; primary manufacturing in Hangzhou, Zhejiang, China)
|
Profiled | — | — | 0 programs |